# Tivozanib As Maintenance Therapy In GYN

> **NCT01972516** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Tivozanib

## Key facts

- **NCT ID:** NCT01972516
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2015-07
- **Final completion:** 2016-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** due to slow accrual
- **Last updated:** 2017-06-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972516, "Tivozanib As Maintenance Therapy In GYN". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01972516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*